Find Academic Supervisors

Rhonda Goldman is a Full Professor in the Clinical Psychology Department at The Chicago School of Professional Psychology in Chicago, Illinois. She is a licensed Clinical Psychologist in Illinois and runs her private practice, Emotion-focused Therapy, Chicago, where she sees both couples and individuals. Dr. Goldman is a founding board member of the International Society of Emotion-focused Therapy and serves as President of the Emotion-focused Therapy Institute. Dr. Goldman earned her academic credentials from York University in Toronto, Ontario, Canada, receiving her Bachelor of Arts in 1987, Master of Arts in 1991, and Doctor of Philosophy in Clinical Psychology in 1997. She taught at the Illinois School of Professional Psychology for 22 years before transitioning to her current position at The Chicago School of Professional Psychology following the closure of the Illinois School. Dr. Goldman is a leading expert in Emotion-Focused Therapy (EFT), a therapeutic approach that integrates elements of client-centered therapy, Gestalt therapy, and modern emotion theory. Her research focuses on EFT for couples, emotional processes, empathy, vulnerability, depression, case formulation, and self-soothing. She has authored six texts on EFT and two professional videos published by the American Psychological Association. Dr. Goldman teaches graduate courses in Humanistic and Experiential Psychotherapy, Psychotherapy Seminars, and Emotion-Focused Therapy, emphasizing the importance of emotional processing in therapeutic change. Dr. Goldman's publications demonstrate a consistent focus on advancing Emotion-Focused Therapy through both theoretical development and practical application. Her work spans individual therapy, couples therapy, case formulation, and therapist training, with recent emphasis on adapting EFT for online delivery. Her research shows how emotional awareness and processing serve as central mechanisms of change in psychotherapy, with applications across various clinical issues including depression and relationship distress. Dr. Goldman is actively involved in professional organizations that support the development and dissemination of Emotion-Focused Therapy. She serves as a founding board member of the International Society for Emotion-focused Therapy, past-president of the Society for the Exploration of Psychotherapy Integration, Action-Editor for the Journal of Person-centered and Experiential Psychotherapies, and member of the Society for Psychotherapy Research. As an educator and clinician, Dr. Goldman has mentored numerous professionals in the field of psychotherapy. She travels internationally conducting training workshops for mental health professionals in Emotion-focused therapy for Couples and Individuals across Europe, Asia, and North America. Her work bridges research and practice, emphasizing the importance of emotional processing in therapeutic change while maintaining a strong commitment to evidence-based practice. Dr. Goldman co-founded the Emotion-focused Therapy Institute (EFTI), which facilitates and fosters training and educational opportunities for psychologists and therapists interested in incorporating EFT into their professional practices. Through EFTI and her international workshops, she has created a global community of practitioners dedicated to advancing Emotion-Focused Therapy.

• Clinical Psychology
• Emotion-Focused Therapy
• Psychotherapy
• +7 more

John Oakey is a Professor and Graduate Coordinator in the Department of Chemical and Biomedical Engineering at the University of Wyoming, with additional affiliations to the INBRE Program, Molecular and Cellular Life Sciences Program, and Materials Science and Engineering Program. Education Postdoctoral Fellow, Center for Engineering in Medicine, Massachusetts General Hospital & Harvard Medical School (2007–2010) Ph.D. Chemical Engineering, Colorado School of Mines (2003) M.S. Chemical Engineering, Colorado School of Mines (1999) B.S. Chemical Engineering, Penn State University (1997) Research Interests Oakey’s laboratory integrates fluid dynamics, colloidal science and materials science to understand how biological systems behave under flow, on surfaces and within complex 3-D geometries. A unifying theme is the use of microfabrication and microfluidics to create new diagnostic, prognostic and therapeutic platforms. Current thrusts include: Heterogeneous biomaterials: self-assembled particulate tissue scaffolds whose mechanical and transport properties can be temporally programmed. Inertial microfluidics: exploiting lift forces for membrane-free particle sorting, enrichment and diagnostics. Multi-temporal analysis by flow cytometry: development of closed-loop, high-throughput microfluidic cytometers for longitudinal single-cell studies. Publication Trends From 2025 back to 2010, Oakey’s articles reveal a consistent trajectory that marries fundamental physics (microtubule mechanics, inertial focusing) with translational applications (cell encapsulation, tissue scaffolds, drug delivery). Recent work (2023-2025) increasingly targets injectable granular hydrogels, single-cell therapeutic delivery and sustainable carbon-sequestering living materials, demonstrating an evolution from microscale transport phenomena to macroscopic biomedical and environmental impact. Scientific Awards No named awards are listed in the supplied text. Advising & Coordination Roles As Graduate Coordinator for the Department of Chemical and Biomedical Engineering, Professor Oakey oversees graduate program development and student mentoring. While no individual students are named, his role implies active supervision of M.S. and Ph.D. advisees in chemical and biomedical engineering. Laboratory & Teams The Oakey Research Group operates from the Energy and Environmental Research Building (EERB 435A) at the University of Wyoming. The lab enjoys R1-level research infrastructure and collaborates broadly with the Wyoming INBRE network, the Molecular and Cellular Life Sciences Program, and the Materials Science and Engineering Program.

• Microfluidics
• Microscale transport phenomena
• Tissue engineering and regenerative medicine
• +4 more

Youngjae You is a Professor of Empire Innovation in the Department of Pharmaceutical Sciences at the University at Buffalo School of Pharmacy. His research focuses on Antibody-Drug Conjugates, Cancer Chemotherapy, Medicinal Chemistry, and Targeted Drug Delivery. He holds adjunct roles at the University of Oklahoma Health Sciences Center and has led numerous grants totaling over $10 million in funding. Key awards include the 2019 Professor of Empire Innovation title and multiple DoD/CDMRP grants. His work emphasizes prodrug design, photodynamic therapy, and combination therapies. Education : PhD in Pharmaceutical Chemistry, Chungnam National University (2001) MS in Pharmaceutical Chemistry, Chungnam National University (2000) BPharm, Chungnam National University (1994) Research Interests : Dr. You specializes in developing light-activatable prodrugs for targeted cancer therapies, including far-red/NIR light-activated delivery systems. His work integrates quantitative pharmacokinetic modeling, singlet oxygen dynamics, and receptor-targeted drug conjugation to enhance therapeutic efficacy while minimizing off-target effects. Key applications include bladder, breast, and ovarian cancers. Funding Highlights : NIH/NIGMS: $1.37M (2023-2027) for light-responsive drug delivery National Cancer Institute: $2.1M (2022-2027) for bladder cancer treatments DoD/CDMRP/PRCRP: $392K (2017-2020) for photodynamic-chemotherapy combinations Awards : PHF Presidential Professorship (2018) American Cancer Society Research Scholar Grant (2013) Multiple DoD/CDMRP Idea Awards Service & Grants : Serves as Principal Investigator on 8 major grants. Active reviewer for Wellcome Trust, NIH, and international funding agencies. Holds patents on BODIPY derivatives and singlet oxygen-labile linkers. Lab & Collaborations : Leads the You Lab at UB, collaborating with bioengineers and clinicians to advance photomedicine and targeted drug delivery systems. Engaged in multidisciplinary teams addressing spatiotemporal control in cancer treatments.

• Antibody-Drug Conjugates
• Cancer Chemotherapy
• Medicinal Chemistry
• +3 more

Michel M. Maharbiz is a Professor in the Department of Electrical Engineering and Computer Science at the University of California, Berkeley. He leads research on miniaturized bioelectronic interfaces, including neural dust implants and cyborg insects. He holds affiliations with the Berkeley Sensor & Actuator Center (BSAC), Center for Neural Engineering & Prostheses (CNEP), and SWARM Lab. His education includes a Ph.D. in EECS from UC Berkeley (2003) and a B.S. in EE from Cornell University (1997). Maharbiz's research integrates MEMS, ultrasonic systems, and synthetic biology to develop wireless neural interfaces, implantable sensors, and biohybrid devices. Key focus areas are neural dust technology for peripheral nerve recording, magnetoelastic strain sensors for medical applications, and electrochemical biosensing using bacterial flagellar motors. His publications emphasize neural interfaces, ultrasonic implants, and biomedical monitoring. Recent articles explore ultrasonic power delivery (2025), radiation detectors for oncology (2025), and fracture-healing smart plates (2019). Trends include miniaturization of wireless implants, closed-loop therapeutic systems, and novel biomaterials. Scientific Awards: McKnight Technological Innovations in Neuroscience Award (2017) Chan-Zuckerberg Biohub Investigator (2017) NSF CAREER Award (2009) MIT TR10 Top Emerging Technology (2009) Bakar Fellows Spark Award (2012) He directs the Maharbiz Lab, advancing neural dust and bioelectronic interfaces. Projects include impedance-based fracture monitoring, carbon fiber neural arrays, and hernia repair sensors. Funding includes NSF and industry partnerships for implantable device development.

• Neural Interfaces
• Micro/Nano Electro Mechanical Systems (MEMS)
• Biosystems & Computational Biology
• +3 more

Allison Ross Eckard, MD is Professor in the Departments of Pediatrics and Medicine at the Medical University of South Carolina (MUSC) College of Medicine, serving as Division Chief for Pediatric Infectious Diseases and Director of MUSC's Ryan White Pediatric HIV Clinic and HIV Transition Clinic. She maintains an adjunct faculty position at Emory University and holds board certification in Pediatrics and Pediatric Infectious Diseases. Her primary research focuses on metabolic, cardiovascular, and nutritional complications of chronic HIV and antiretroviral therapy across age groups, with emphasis on inflammation's role in comorbidities like cardiovascular disease and bone disorders. Current investigations include NIH R01-funded research on interventions for weight gain and abdominal fat in HIV, vitamin D supplementation, and statin therapy. She has published nearly 60 peer-reviewed papers on HIV pathogenesis and treatment optimization. Dr. Eckard co-chairs the DHHS panel for Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children and serves on the DHHS panel for Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV . Her clinical work specializes in comprehensive HIV care for children through young adults, with particular focus on adolescent/young adult transition issues and global health initiatives through Lespwa Timoun in Haiti. Recent efforts include developing COVID-19 treatment guidelines for children and school safety protocols. HIV Specialist certification (American Academy of HIV Medicine) Fellow, Infectious Diseases Society of America Fellow, Pediatric Infectious Diseases Society Fellow, HIV Medical Association Member, HIV Medical Association's 'Ending the HIV Epidemic' working group She leads MUSC's HIV education initiatives and serves as inpatient consultant for pediatric infectious diseases, with advanced training in tropical medicine. Her NIH-funded research examines targeted interventions to minimize comorbidity development in HIV, while her clinical leadership spans the Ryan White HIV program, transition clinics, and global health partnerships.

• HIV-related cardiometabolic complications
• Antiretroviral therapy optimization
• Pediatric infectious diseases
• +7 more

Hai-Quan Mao is a Professor of Materials Science and Engineering at Johns Hopkins University, with a joint appointment in the Biomedical Engineering Department (School of Medicine). He directs the Institute for NanoBioTechnology (INBT) and leads the Translational Tissue Engineering Center. His research focuses on biomaterials, regenerative engineering, and immunoengineering, particularly developing nanomaterials for therapeutic delivery and tissue regeneration. Mao holds 35 U.S. patents, co-founded two biotech companies, and received prestigious awards including National Academy of Inventors Fellow and NSF CAREER Award. Education: BS in Chemistry (1988) and PhD in Polymer Chemistry (1993) from Wuhan University. Postdoctoral training at Johns Hopkins (1995–1998), followed by roles at Johns Hopkins Singapore (1999–2003) before joining the Whiting School faculty. Research emphasizes nanofiber scaffolds for liver/nerve regeneration, DNA/lipid nanoparticle engineering for gene therapy, and artificial lymph node matrices for immunotherapy. His lab translates biomaterials innovations into clinical applications, with NIH-funded projects addressing cancer, malaria, and tissue damage. Awards include over 60 provisional patents, multiple Johns Hopkins translational awards, and Thalheimer Awards for research. He serves as associate editor of Biomaterials and editorial board member of major journals. Lab activities include scalable nanoparticle manufacturing, machine learning for material design, and collaborations with industry/clinical partners. Recent work includes lipid nanoparticle optimization for mRNA vaccines and exosome-based therapies for Crohn’s disease.

• Biomaterials
• Regenerative Engineering
• Therapeutic Delivery
• +3 more

Bradley D. Olsen is a full professor in the Department of Chemical Engineering at the Massachusetts Institute of Technology (MIT), where he leads research at the intersection of polymer science, soft matter physics, and bioengineering. His work focuses on designing materials for critical applications in biotechnology, hemostasis, and sustainable polymer development while advancing fundamental understanding of polymer network mechanics and self-assembly. Education: Ph.D. in Chemical Engineering, University of California Berkeley (2007) S.B. in Chemical Engineering, Massachusetts Institute of Technology (2003) Olsen's research spans protein-based materials, block copolymer phase behavior, and mechanochemical hydrogels. He has pioneered methods for quantifying polymer network topology, developing hemostatic nanoparticles, and creating bio-inspired materials for selective biomolecular transport and medical applications. His recent publications emphasize data-driven approaches to polymer characterization and educational outreach in materials science. Scientific Awards: American Physical Society (APS) Fellow (2023) Fulbright Amazonia Scholar (2023) Alexander and I. Michael Kasser Chair in Chemical Engineering (2021) ACS Macro Letters Young Investigator Award (2021) MIT Committed to Caring Honor (2019) AIChE Owens Corning Early Career Award (2019) APS Dillon Medal (2018) Kavli Emerging Leader in Chemistry (2017) ACS Polymer Division Fellow (2016) Camille Dreyfus-Teacher Scholar (2015) Alfred P. Sloan Research Fellow (2014) NSF Career Grant (2013) NIH Postdoctoral Fellowship (2008-2009) Hertz Fellow (2003-2007) Barry M. Goldwater Scholarship (2002) Olsen has received significant grant support including NSF Career (2013) and AFOSR (2012) awards. His teaching activities include innovative international outreach like the 2025 soccer-themed science camp in Brazil. The Olsen Group at MIT explores advanced materials with applications ranging from trauma care to sustainable polymers.

• Polymer Science
• Materials Engineering
• Soft Condensed Matter Physics
• +4 more

Weiping Tang is a Professor of Pharmaceutical Sciences and Chemistry at the University of Wisconsin-Madison, holding the Janis Apinis Professorship in the School of Pharmacy and the Vilas Distinguished Achievement Professorship. He also serves as Director of the Medicinal Chemistry Center at the School of Pharmacy and maintains a faculty appointment with the Department of Chemistry in the College of Letters and Science. Janis Apinis Professor of Pharmaceutical Sciences Vilas Distinguished Achievement Professor Director of Medicinal Chemistry Center Faculty Appointment with Department of Chemistry Dr. Tang received his B.S. in Chemistry from Peking University in 1997, M.S. in Chemistry from New York University in 1999, Ph.D. in Organic Chemistry from Stanford University in 2005, and completed a postdoctoral fellowship in Medicinal Chemistry, Chemical Biology and Drug Discovery at Harvard University in 2007. Dr. Tang's research program focuses on drug discovery for cancer, infectious diseases, and neurodegenerative disorders through three interconnected areas: Organic Synthesis (advancing glycoscience through novel carbohydrate synthesis technologies), Medicinal Chemistry (developing small molecules that selectively remove disease-associated proteins), and Chemical Biology (dissecting biological pathways using novel small molecule probes). His group operates as an interdisciplinary team where chemists and biologists collaborate closely on drug discovery projects, with particular emphasis on developing novel degraders for disease-causing proteins. Analysis of Dr. Tang's publication record reveals a significant shift toward targeted protein degradation technologies, particularly PROTACs and molecular glues, while maintaining strong foundations in carbohydrate chemistry. His most impactful recent work includes developing degraders for extracellular and membrane proteins (previously considered 'undruggable'), creating rapid synthesis platforms like Rapid-TAC and Rapid-Glue, and advancing understanding of ternary complex formation for novel PROTAC design. His research spans both chemical methodology development and therapeutic applications across multiple disease areas. Vilas Distinguished Achievement Professorship Janis Apinis Professorship Numerous high-impact publications in leading chemistry and pharmacology journals Editor's pick and hot paper designations for significant contributions Dr. Tang mentors a diverse team of graduate students, postdoctoral fellows, and staff scientists with expertise spanning synthetic chemistry, medicinal chemistry, carbohydrate chemistry, computational chemistry, biochemistry, and cell biology. His group has developed innovative platforms for the rapid synthesis of protein degraders and has made significant contributions to understanding the mechanisms of action for these novel therapeutics. Current research includes developing selective degraders for cancer targets like RIPK1, BRD4, and CARM1, as well as advancing delivery systems for clinical translation. The Tang Research Group maintains state-of-the-art facilities within the School of Pharmacy at UW-Madison, equipped for comprehensive chemical synthesis, compound characterization, and biological evaluation. The group actively collaborates with researchers across campus and with industry partners to advance discoveries toward clinical applications, with particular focus on cancer therapeutics and protein degradation technologies.

• Targeted Protein Degradation
• PROTACs
• Medicinal Chemistry
• +5 more

Dr. Kai Gong is an Assistant Professor of Civil and Environmental Engineering at Rice University, with affiliations at the Rice Advanced Materials Institute and Ken Kennedy Institute. His research focuses on sustainable infrastructure materials, environmental sustainability, and materials science. He holds a Ph.D. in Civil & Environmental Engineering and Materials Science from Princeton University, an MEngSci from Monash University (Australia), and dual B.S. degrees from Monash University and Central South University (China). Research Interests: Development of durable, sustainable infrastructure materials Waste encapsulation and conversion to value-added products Carbon mineralization and utilization Advanced characterization techniques (synchrotron/neutron scattering) Data-driven modeling and atomistic simulations Notable Awards: 2023 Le Chatelier Medal (Cement and Concrete Research) 2024 Giatec Award for Best Paper in Sustainability Walbridge Fund Graduate Award (2019) His work integrates computational methods (e.g., molecular dynamics) with experimental techniques to address decarbonization challenges in infrastructure. The Gong Research Group actively seeks motivated researchers for opportunities in sustainable materials innovation.

• Sustainable Infrastructure Materials
• Environmental Sustainability
• Materials Science
• +4 more

Hyun (Michel) Koo is a Professor at the University of Pennsylvania School of Dental Medicine , with affiliations in the Department of Orthodontics , Division of Community Oral Health , and Division of Pediatric Dentistry . As Co-Founder and Co-Director of the Center for Innovation & Precision Dentistry (CiPD) , he leads interdisciplinary efforts merging bioengineering, nanotechnology, and oral health research. Education : DDS and PhD Research Focus : Biofilms, bacterial-fungal interactions, and nanotechnology for oral disease prevention Leadership : Co-Director of CiPD; key roles in training programs like NIDCR-sponsored R90 and T90/R90 Dr. Koo’s research explores biofilm mechanisms in oral infectious diseases, particularly childhood caries, through engineering methods and microrobotics . His team developed micron-scale robots for automated biofilm eradication and FDA-approved nanoparticles for caries prevention. Collaborations with Penn Engineering, including Dr. Daeyeon Lee and Dr. Kacy Cullen, emphasize translational approaches. The 15 most recent publications highlight his work in nanorobotics , interkingdom biofilms , and precision diagnostics . Articles span 2025–2024 and address topics like adaptive micromotors , biofilm matrix degradation , and single-cell microbial interactions . These emphasize his focus on targeted therapies and biofilm microenvironment engineering . Key Awards : Elected Fellow, American Association for the Advancement of Science (AAAS) IADR Distinguished Scientist Award for innovative dental research Dr. Koo trains next-generation researchers through the CiPD NIDCR T90/R90 Postdoctoral Training Program , mentoring fellows like Smruti Nair (ACE2 Chewing Gum development) and Zhi Ren (K99 awardee). His work intersects with Penn Health-Tech, CT3N , and Penn Institute for Biomedical Informatics , fostering transdisciplinary innovation.

• Biofilms
• Oral Infectious Diseases
• Nanotechnology
• +3 more

Kelly Arnold is an Associate Professor in the Department of Biomedical Engineering at the University of Michigan. Her research integrates systems engineering principles with immunology to investigate variability in immune responses across infection, vaccination, and injury, with a focus on computational modeling and clinical translation. Research Focus Systems-level immune response modeling Vaccination and antibody functionality Vaginal microbiome-host interactions Chronic lung disease progression Computational serology and proteomics Recent Work Her 2025 studies examine SARS-CoV-2 vaccination responses in cancer patients and computational frameworks for vaginal probiotics. Earlier works (2024-2007) span COPD progression, lupus fibrosis, HIV susceptibility, and tissue engineering for fertility preservation. Methodologies include proteomic profiling, network modeling, and microfluidic systems.

• Biomedical Computation and Modeling
• Drug Delivery and Therapeutics
• Systems Immunology
• +5 more

Dr. Kenneth Joseph is an Associate Professor in the Department of Computer Science and Engineering at the University at Buffalo , part of the School of Engineering and Applied Sciences . He serves as Associate Director of the Institute for Artificial Intelligence and Data Science and leads the Computation and Equity Lab (cubelab) , focusing on social inequality through computational measures and models. Education: PhD, MS, and BS in Societal Computing from Carnegie Mellon University (2016, 2012, 2010) Research Interests: Computational Social Science, Network Science, Gender Studies, and AI for Social Good Notable Work: Gender disparities in academia, predictive modeling for foster care and urban policy, and social media rumor analysis Awards: UB Exceptional Scholar—Young Investigator Award (2021) Advising: Mentored students like Yuhao Du, Jason Yan, Arjunil Pathak, and Navid Madani on projects spanning Twitter bios, foster youth services, and algorithmic fairness.

• Computational Social Science
• Social Inequality
• Network Science
• +3 more

Rotem Karni, PhD, is an Associate Professor of Genetics at the Perelman School of Medicine, University of Pennsylvania, Philadelphia. He leads a research lab focused on understanding how alternative RNA splicing contributes to cancer and genetic diseases, with a strong emphasis on translating these findings into RNA-based therapies. Karni's lab develops decoy oligonucleotides, small molecules, and splice-switching technologies to modulate splicing factors and enhance immunotherapy. Education BSc in Biological Chemistry from The Hebrew University of Jerusalem (1997) PhD in Biological Chemistry from The Hebrew University of Jerusalem, Israel (2002) Postdoctoral Fellowship at Cold Spring Harbor Laboratory, NY (2002-2007) Karni's research explores the deregulation of alternative splicing in oncogenesis, particularly how splicing factors like RBFOX2 and S6K1 influence metastasis, DNA repair, and immune checkpoint modulation. His team investigates m6A RNA modifications for stabilizing mutant genes, with applications in Duchenne Muscular Dystrophy and pancreatic cancer. The lab's work is commercialized through biotech companies: SKIP Therapeutics, Andlit Therapeutics, and RNAble. Selected Research Trends RNA mis-splicing and neoantigen generation (2025) Splicing factor inhibition for tumor suppression (2023) Metastatic splicing signatures in pancreatic cancer (2023) Immune checkpoint splicing in cancer immunotherapy (2021) m6A modulation for mRNA stabilization (2023) Advising & Collaborations Karni has mentored numerous PhD and postdoctoral researchers, many of whom now hold leadership roles in academia, biotech, and medical institutions globally. His lab collaborates extensively on projects involving RNA innovation, including partnerships with the Institute for RNA Innovation. Contact Department of Genetics & Institute for RNA Innovation, One uCity Square, Room 4018, Philadelphia, PA 19104 Phone: 215-898-5072 Email: Rotem.Karni@Upenn.edu

• Alternative RNA Splicing
• RNA Biology
• Cancer Therapy
• +4 more

Virgil Percec is the P. Roy Vagelos Professor of Chemistry at the University of Pennsylvania, affiliated with the School of Arts & Sciences and the Department of Chemistry. His research focuses on organic, supramolecular, and macromolecular chemistry, with an emphasis on self-assembly, drug delivery systems, and biomimetic nanosystems. He holds a B.S. and Ph.D. from institutions in Jassy, Romania, and conducted postdoctoral research at the University of Freiburg and the University of Akron. Research Interests: Percec’s work integrates synthetic methods, catalysis, and structural biology to design functional nanosystems. Key areas include hierarchical folding, supramolecular chirality, and synthetic mimics of biological membranes. His lab explores mRNA delivery systems using Janus dendrimers and studies self-organized structures like helical columns and quasicrystals. Recent Articles: His recent publications highlight advancements in mRNA delivery mechanisms, supramolecular architectures, and polymer synthesis innovations. The group’s work often involves interdisciplinary collaborations, bridging chemistry, materials science, and bioengineering. Awards: Percec was elected a Foreign Member of the Academia Europaea (2020) and delivered the inaugural ACS Kavli Lecture (2011). His lab has trained numerous students and postdocs, including Juncheng Lu (Master’s Capstone Award recipient) and Devendra Maurya (SET-LRP research). Labs & Teams: The Percec Research Laboratory at Penn develops cutting-edge biomaterials and supramolecular systems. The group collaborates globally, with projects funded by grants exploring nanotechnology and drug delivery.

• Organic Chemistry
• Supramolecular Chemistry
• Nanotechnology
• +4 more

Andrew D. White is an Associate Professor of Chemical Engineering at the Hajim School of Engineering & Applied Sciences, University of Rochester. He holds a PhD from the University of Washington (2013). His research focuses on automating scientific discovery through AI, particularly leveraging large language models (LLMs) and deep learning techniques in chemistry. His lab develops agents that integrate literature analysis, hypothesis generation, and experimental design to advance fields like molecular dynamics and drug discovery. Education: PhD in Chemical Engineering, University of Washington, 2013 BS/MS (not explicitly stated in text, inferred from career timeline) Research Interests: Large language models for scientific automation Deep learning applications in chemistry and materials science Molecular dynamics simulations Scientific agents and autonomous systems Publications: His work includes groundbreaking studies on closed-loop AI systems for chemistry, federated learning in molecular property prediction, and multi-agent systems for drug discovery. Recent highlights include the Robin system and ChemCrow tools. Awards: Recipient of the NSF Career Award (2018), NIH Outstanding Investigator Award (2020), and the Curtis Teaching Award (2019). He also advises biotech companies and serves on the National Academy of Sciences' Chemical Sciences Roundtable. Grants & Funding: Supported by DOE, NSF (multiple grants including CBET-1751471), NIH (R35GM137966), and LLNL projects. Collaborates with institutions like Argonne National Lab and Qubit Pharmaceuticals. Labs & Teams: Leads the White Lab at Rochester and co-founded FutureHouse, a nonprofit advancing AI-driven scientific discovery. Supervises a multidisciplinary team of PhD students and postdocs in computational chemistry, AI, and biophysics.

• Large language models
• Deep learning in chemistry
• Molecular dynamics
• +5 more